621 related articles for article (PubMed ID: 16885745)
1. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
2. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang P; Gao WY; Turner S; Ducatman BS
Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
[TBL] [Abstract][Full Text] [Related]
3. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
Yerushalmi R; Nordenberg J; Beery E; Uziel O; Lahav M; Luria D; Fenig E
Exp Oncol; 2007 Jun; 29(2):126-31. PubMed ID: 17704745
[TBL] [Abstract][Full Text] [Related]
4. Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents.
Ongkeko WM; An Y; Chu TS; Aguilera J; Dang CL; Wang-Rodriguez J
Laryngoscope; 2006 Aug; 116(8):1390-6. PubMed ID: 16885742
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
6. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
7. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
[TBL] [Abstract][Full Text] [Related]
8. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
Wang LH; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
10. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
[TBL] [Abstract][Full Text] [Related]
11. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
12. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
13. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
15. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
Johnson FM; Yang P; Newman RA; Donato NJ
J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661
[TBL] [Abstract][Full Text] [Related]
17. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
18. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
19. Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
Ranza E; Bertolotti A; Facoetti A; Mariotti L; Pasi F; Ottolenghi A; Nano R
Anticancer Res; 2009 Nov; 29(11):4575-8. PubMed ID: 20032406
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
